HSK 39297
Alternative Names: HSK-39297Latest Information Update: 26 Aug 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Paroxysmal nocturnal haemoglobinuria
- Phase I Kidney disorders
Most Recent Events
- 26 Aug 2024 Phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria (Treatment-naive) in China (PO) (NCT06561841)
- 25 Dec 2023 Phase-I clinical trials in Kidney disorders (In volunteers) in China (PO) (NCT06350279)